Table 1 Primary diseases leading to anti-TNFα treatment implementation; number (%) of patients in all cases
From: Tuberculosis in pediatric patients treated with anti-TNFα drugs: a cohort study
Primary disease | Patients (n = 221) | Treatments (n = 261) |
|---|---|---|
Juvenile idiopathic arthritis | 163 (73.6) | 195 (74.7) |
Polyarticular JIA, positive RF | 6 (2.7) | 7 (3.8) |
Polyarticular JIA, negative RF | 40 (18.1) | 48 (18.4) |
Oligoarticular JIA | 70 (31.7) | 88 (33.7) |
Enthesitis-related arthritis | 24 (10.9) | 24 (9.2) |
Psoriasic arthritis | 11 (5.0) | 13 (5.0) |
Undifferentiated disease | 12 (5.4) | 15 (5.7) |
Blau syndrome | 1 (0.5) | 2 (0.8) |
Tumor necrosis factor associated periodic syndrome | 1 (0.5) | 1 (0.4) |
PAPA syndrome | 1 (0.5) | 1 (0.4) |
Chronic plantar fascitis | 1 (0.5) | 1 (0.4) |
Inflammatory bowel disease | ||
Crohn’s disease | 36 (16.3) | 39 (14.9) |
Ulcerative colitis | 10 (4.5) | 11 (4.2) |
Inflammatory diseases of the eye | ||
Uveitis | 7 (3.2) | 10 (3.8) |
Pars planitis | 1 (0.5) | 1 (0.4) |